Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
127 hedge funds and large institutions have $1.17B invested in Avadel Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 43 increasing their positions, 29 reducing their positions, and 22 closing their positions.
67% more funds holding in top 10
Funds holding in top 10: 6 → 10 (+4)
64% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 22
48% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 29
45% more capital invested
Capital invested by funds: $809M → $1.17B (+$364M)
12.87% more ownership
Funds ownership: 63.82% → 76.68% (+13%)
12% more funds holding
Funds holding: 113 → 127 (+14)
38% less call options, than puts
Call options by funds: $28M | Put options by funds: $45.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
+$39.7M |
| 2 |
RI
RTW Investments
New York
|
+$27.6M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$26.7M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$25.1M |
| 5 |
Millennium Management
New York
|
+$23.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
-$23.2M |
| 2 |
Morgan Stanley
New York
|
-$19.6M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$7.03M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$5.24M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.26M |
AVDL Hedge Fund Activity: Q1 2024 in Review
127 of the 6,947 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q1 2024, worth a combined $1.17B — up 45% from $809M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new AVDL positions and 22 closed out — a net gain of 14 holders — while 43 added to existing stakes and 29 trimmed.
The largest buyer was Braidwell, opening a new position worth an estimated $39.7M. The largest seller was Cowen and Company, exiting entirely with an estimated $23.2M sold.
- 127 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q1 2024, up from 113 in Q4 2023.
- Funds reported $1.17B of Avadel Pharmaceuticals stock for Q1 2024, up 45% quarter-over-quarter.
- 36 funds opened new Avadel Pharmaceuticals positions in Q1 2024 and 22 closed out, a net change of +14 holders.
- The largest Avadel Pharmaceuticals buyer in Q1 2024 was Braidwell, an estimated $39.7M added.
- The largest Avadel Pharmaceuticals seller in Q1 2024 was Cowen and Company, an estimated $23.2M sold.
Based on aggregated 13F filings for Q1 2024.